Epitel Receives FDA Approval for REMI Remote EEG Monitoring System and REMI Vigilenz AI

Epitel has received US FDA 510(k) clearance of two new innovative technologies, REMI™ Remote EEG Monitoring System for Ambulatory (home) use and REMI Vigilenz™ AI for Event Detection. REMI for Ambulatory allows EEG recordings to be made in outpatient and home settings over an extended period of time, while REMI Vigilenz AI for Event Detection analyses and flags REMI EEG recordings for potential electrographic seizures to aid in ease and accuracy of interpretation.

REMI Ambulatory and REMI Vigilenz AI For Event Detection will help patients and providers make better-informed treatment decisions, and we are excited about how these two advances will shift the paradigm of brain health monitoring,” said Mark Lehmkuhle, Chief Executive Officer and Co-Founder of Epitel.

en_GBEnglish (UK)